These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors. Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450 [TBL] [Abstract][Full Text] [Related]
3. Differential selectivity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in cultured human B lymphocytes and mouse L1210 leukemia. Au JL; Rustum YM; Minowada J; Srivastava BI Biochem Pharmacol; 1983 Feb; 32(3):541-6. PubMed ID: 6221728 [TBL] [Abstract][Full Text] [Related]
4. Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines. Cao D; Russell RL; Zhang D; Leffert JJ; Pizzorno G Cancer Res; 2002 Apr; 62(8):2313-7. PubMed ID: 11956089 [TBL] [Abstract][Full Text] [Related]
5. Comparing cell kinetic studies of the effect of ftorafur and 5-fluorouracil on the L 1210 ascites tumor. Schultze B; Jellinghaus W; Weis G; Müller V; Maurer W J Cancer Res Clin Oncol; 1981; 100(1):25-40. PubMed ID: 6787060 [TBL] [Abstract][Full Text] [Related]
6. Modulation of the effects of fluoropyrimidines on toxicity and tumor inhibition in rodents by uridine and thymidine. Hartmann HR; Bollag W Med Oncol Tumor Pharmacother; 1986; 3(2):111-8. PubMed ID: 2943952 [TBL] [Abstract][Full Text] [Related]
7. Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding. Curtin NJ; Bowman KJ; Turner RN; Huang B; Loughlin PJ; Calvert AH; Golding BT; Griffin RJ; Newell DR Br J Cancer; 1999 Aug; 80(11):1738-46. PubMed ID: 10468290 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and antitumor activity of a series of ftorafur analogues: the effect of varying electronegativity at the 1'-position. Holshouser MH; Shipp AM; Ferguson PW J Med Chem; 1985 Feb; 28(2):242-5. PubMed ID: 3918171 [TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy with cyclophosphamide and ftorafur against advanced L1210 murine leukemia. Grossie VB; Rosenblum MG; Loo TL Cancer Treat Rep; 1982 Aug; 66(8):1631-4. PubMed ID: 6809329 [TBL] [Abstract][Full Text] [Related]
10. Synergistic effects of Actinobacillus suis cells in combination with 5-fluorouracil on mice bearing murine L1210 leukemia cells. Watanabe T; Itoh S Cancer Immunol Immunother; 1997 Jun; 44(4):216-20. PubMed ID: 9222280 [TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of metabolites of 1-hexylcarbamoyl-5-fluorouracil and related compounds against L1210 leukemia in vivo and L5178Y lymphoma cells in vitro. Hoshi A; Yoshida M; Inomata M; Iigo M; Ando N; Kuretani K J Pharmacobiodyn; 1980 Sep; 3(9):478-81. PubMed ID: 7463306 [TBL] [Abstract][Full Text] [Related]
12. The combination 5-fluorouracil/levamisole induces enhanced rat Kupffer cell-mediated cytotoxicity in vitro against the syngeneic colon adenocarcinoma cell line CC531. Schuurman B; Sirovich I; Heuff G; van der Wilt CL; Peters GJ; Beelen RH; Meyer S J Surg Oncol; 1995 Nov; 60(3):180-4. PubMed ID: 7475068 [TBL] [Abstract][Full Text] [Related]
13. Studies to increase the antitumor activity of 1-(tetrahydro-2-furanyl)-5-fluorouracil and its metabolic aspects by combined administration with L-cysteine. Kawabata N; Sugiyama S; Kuwamura T; Satoh T; Kitagawa H Jpn J Pharmacol; 1983 Aug; 33(4):735-47. PubMed ID: 6415326 [TBL] [Abstract][Full Text] [Related]
14. [Effect of cepharanthine on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207)--5-fluorouracil delivery into tumor tissue]. Ono M Nihon Gan Chiryo Gakkai Shi; 1989 Jul; 24(7):1379-92. PubMed ID: 2509603 [TBL] [Abstract][Full Text] [Related]
15. Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Keyomarsi K; Moran RG Cancer Res; 1986 Oct; 46(10):5229-35. PubMed ID: 2944577 [TBL] [Abstract][Full Text] [Related]
16. Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice. Fujimoto S Biol Pharm Bull; 2006 Nov; 29(11):2260-6. PubMed ID: 17077525 [TBL] [Abstract][Full Text] [Related]
17. Comparative physiologic dispositions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil in mice bearing solid L1210 lymphocytic leukemia. Chadwick M; Chang C Cancer Treat Rep; 1976 Jul; 60(7):845-55. PubMed ID: 137772 [TBL] [Abstract][Full Text] [Related]
18. [Mode of action of fluoropyrimidines, in relation to their clinical application]. Suga S; Kimura K; Kubo K; Aoyama H; Inukai N; Kato K; Horiuchi T; Sawada H; Yokoyama Y Gan To Kagaku Ryoho; 1984 Nov; 11(11):2301-6. PubMed ID: 6497396 [TBL] [Abstract][Full Text] [Related]
19. Partial synchronization of L1210 cells by 5-fluorouracil and its use in drug combinations. Bhuyan BK; Blowers CL; Neil GL; Bono VH; Day KJ Cancer Res; 1977 Sep; 37(9):3204-8. PubMed ID: 560250 [TBL] [Abstract][Full Text] [Related]
20. Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidine resistance in colon cancer in vitro. Mader RM; Sieder AE; Braun J; Rizovski B; Kalipciyan M; Mueller MW; Jakesz R; Rainer H; Steger GG Biochem Pharmacol; 1997 Dec; 54(11):1233-42. PubMed ID: 9416974 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]